Preliminary_results_in_invasive_bladder_cancer_with_transurethral_resection,_neoadjuvant_chemotherapy_and_combined_pelvic_irradiation_plus_cisplatin_chemotherapy._Preliminary_data_are_presented_of_a_clinically_feasible_pilot_study_to_select_a_significant_subgroup_of_patients_among_those_with_muscle-invading_bladder_tumors_for_local_cure_and_bladder_preservation,_while_also_to_offer_all_patients_the_possibility_of_preventing_the_development_of_distant_metastases._Transurethral_debulking_surgical_resection_was_combined_with_neoadjuvant_methotrexate,_cisplatin_and_vinblastine_chemotherapy_plus_2_additional_courses_of_cisplatin_and_4,000_cGy._If_tumor_was_found_on_cystoscopic_re-evaluation_by_biopsy_and_for_cytology_after_cisplatin_and_partial_irradiation_(4,000_cGy.)_immediate_cystectomy_was_advised._If_tumor_was_not_found_consolidation_by_a_radiotherapy_boost_to_a_total_of_6,480_cGy._plus_1_additional_course_of_cisplatin_was_given._Of_53_consecutive_patients_the_planned_treatment_was_completed_in_42_(79%)._With_a_median_followup_of_26_months_(range_15_to_42_months),_72%_of_all_entered_patients_were_alive,_70%_have_not_required_cystectomy_and_74%_have_not_had_distant_metastases._Among_the_42_patients_who_completed_the_planned_protocol_chemotherapy_dose_reductions_were_required_in_39%_for_stomatitis,_bone_marrow_depression_and/or_renal_dysfunction._There_were_2_serious_complications_but_no_treatment-related_sepsis,_deaths_or_significant_renal_dysfunction._Eight_patients_underwent_immediate_radical_cystectomy_because_of_positive_biopsy_and/or_cytology_results_after_4,000_cGy.,_while_34_completed_full_chemotherapy_and_radiotherapy_without_any_significant_bladder_or_bowel_injury._Of_42_patients_22_(52%)_have_maintained_the_bladder_without_any_recurrence,_and_of_those_selected_for_full_chemotherapy_and_radiotherapy_this_number_increased_to_65%._To_date_12_patients_have_persistent_or_recurrent_bladder_tumors:_5_(15%)_had_invasive_tumors_treated_by_cystectomy_and_7_(21%)_had_carcinoma_in_situ_treated_by_intravesical_therapy._The_true_success_of_this_or_other_selective_bladder-preserving_treatments_will_require_3_to_5_years_of_followup_to_be_confident_that_such_treatment_has_sterilized_the_bladder_of_cancer._This_feasibility_study_has_been_clinically_practical,_modestly_well_tolerated_and_encouraging_for_the_significant_proportion_of_patients_with_a_sustained_complete_response_and_for_the_70%_over-all_survival_rate_at_2_years._To_evaluate_critically_the_efficacy_of_methotrexate,_cisplatin_and_vinblastine_chemotherapy_in_the_prevention_of_occult_distant_micrometastases_and_in_increasing_the_rate_of_successful_bladder_preservation,_in_May_1988_we_began_a_randomized_phase_3_trial_with_and_without_neoadjuvant_methotrexate,_cisplatin_and_vinblastine_chemotherapy.